Neoplasms

All Conditions

Nervous System Diseases

Skin and Connective Tissue Diseases

Rare Diseases

Glioma

Brain Neoplasms

Central Nervous System Neoplasms

Pinealoma

Ependymoma

Solitary Fibrous Tumors

Hemangiopericytoma

Hemangioblastoma

Choroid Plexus Neoplasms

Neoplasms, Fibrous Tissue

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Cerebral Ventricle Neoplasms

Neoplasms, Vascular Tissue

Neoplasms, Connective Tissue

Neoplasms, Connective and Soft Tissue

Hemangioma

Hemangioma, Capillary

Germ Cells Tumors

Pineocytoma

Neuroepithelioma

The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.

Observational

EORTC HQ

Jordi Bruna Escuder

Michael Weller

Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on how patients with newly defined brain tumour entities should be treated and what to expect from the current treatments.

The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.

* Tumour tissue specifically stored for the purpose of this project
* Residual biological material ("leftovers") and/or derivatives

Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification

Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Diagnosed According to cIMPACT-NOW Recommendations and the 2021 WHO Classification

Date of surgery that allowed for the first pathological diagnosis up to the date of death (any cause). Patients will be followed up for 5 years after enrolment.

From the date of start of the anti-tumor therapy until the date of first objective progression as determined by the local investigator or the date of patient's death whichever occurs first. Patients will be followed up for 5 years after enrolment.

Recorded from the date start of an anti-tumor therapy until disease progression or start of a new anti-tumor therapy. Patients will be followed up for 5 years after enrolment.

European Organisation for Research and Treatment of Cancer - EORTC

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification	NCT05259605	Glioma Glioneuronal Tu... Choroid Plexus ... Pineal Tumors Germ Cell Tumor Tumor of the Se... Diffuse Midline... Ependymoma Embryonal Tumor Pineal Tumor Hemangiopericyt... Hemangioblastom... Melanocytic Tum...	Observational	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification	NCT05259605	Glioma Glioneuronal Tu... Choroid Plexus ... Pineal Tumors Germ Cell Tumor Tumor of the Se... Diffuse Midline... Ependymoma Embryonal Tumor Pineal Tumor Hemangiopericyt... Hemangioblastom... Melanocytic Tum...	Observational	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC

Spots Global Cancer Trial Database for 2021 who classification